RSS-Feed abonnieren
DOI: 10.1055/s-2004-821288
Georg Thieme Verlag KG Stuttgart · New York
Ziele und Ergebnisse der COSS-Studien
Goal and Results of the COSS StudyPublikationsverlauf
Publikationsdatum:
22. Oktober 2004 (online)
![](https://www.thieme-connect.de/media/hamipla/200405/lookinside/thumbnails/10.1055-s-2004-821288-1.jpg)
Zusammenfassung
Das Osteosarkom ist der häufigste primäre maligne Knochentumor (jährliche Inzidenz: 2 bis 3/Million). Die Versorgung betroffener Kinder, Jugendlicher und Erwachsener aus Deutschland, Österreich und der Schweiz erfolgt seit über 25 Jahren im Rahmen von Studien der Cooperativen Osteosarkom-Studiengruppe (COSS). Etwa 60 % aller in die COSS-Studien eingebrachten Patienten konnten durch einen interdisziplinären Therapieansatz aus kompletter chirurgischer Entfernung des Primärtumors sowie intensiver prä- und postoperativer Chemotherapie geheilt werden. Die COSS-Gruppe überblickt mittlerweile über 3000 solcherart multimodal behandelter Osteosarkompatienten und ist somit weltweit die größte Serie. Die an diesen Patienten gewonnenen Erkenntnisse sollen im Folgenden erläutert werden.
Abstract
Osteosarcoma is the most common primary malignant tumor of bone (annual incidence: 2 - 3/Mio). Ever since 25 years ago, affected children, adolescents, and adults from Germany, Austria, and Switzerland receive their therapy within trials of the Cooperative Osteosarcoma Study Group (COSS). Approximately 60 % of all patients ever entered into COSS-trials could be cured with an interdisciplinary treatment approach consisting of complete surgical removal of the primary tumor plus intensive pre- and postoperative chemotherapy. The COSS-group's database now includes information on more than 3000 osteosarcoma patients treated with such a multimodal approach, the largest series worldwide. The present paper is intended to detail the experience gathered from this cohort.
Schlüsselwörter
Osteosarkom - Cooperative Osteosarkom-Studiengruppe - Therapiestrategien
Key words
Osteosarcoma - Cooperative Osteosarcoma Study Group - therapy strategies
Literatur
- 1 Arndt C, Morgenstern B, Hawkins D, Wilson D, Liedtke R, Miser J. Renal function following combination chemotherapy with Ifosfamide and Cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol. 1999; 32 93-96
- 2 Bielack S S, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?. Eur J Cancer. 1996; 32 1652-1660
- 3 Bielack S S, Erttmann R, Winkler K, Landbeck G. Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989; 25 873-882
- 4 Bielack S S, Jürgens H. In reply to “Comment on ’Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1. 702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols‘ by Ferrari et al. ”. J Clin Oncol. 2002; 20 2910
- 5 Bielack S, Kempf-Bielack B, Branscheid D, Helmke K, Kabisch H, Kotz R, Jürgens H. Relapsed osteosarcoma: An analysis of 576 Cooperative Osteosarcoma Study Group (COSS) patients. Abstract. Chicago; 39th Annual Meeting of the American Society of Clinical Oncology 2003
- 6 Bielack S S, Kempf-Bielack B, Delling G, Exner G U, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002; 20 776-790
- 7 Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, Exner G U, Fuchs N, Göbel U, Graf N, Heise U, Helmke K, von Hochstetter A R, Jürgens H, Maas R, Münchow N, Salzer-Kuntschik M, Treuner J, Veltmann U, Werner M, Winkelmann W, Zoubek A, Kotz R. Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienten. Klin Pädiatr. 1999; 211 260-270
- 8 Bielack S S, Kempf-Bielack B, Winkler K. Osteosarcoma: Relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol. 1996; 15 683-684 (letter)
- 9 Bielack S S, Wulff B, Delling G, Göbel U, Kotz R, Ritter J, Winkler K. Osteosarcoma of the trunk treated by multimodal therapy: Experience of the cooperative osteosarcoma study group COSS. Med Pediatr Oncol. 1995; 24 6-12
- 10 Enneking W F, Spanier S S, Goodman M A. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 1980; 153 106-120
- 11 Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, Brach Del Prever A, Fagioli F, Comandone A, Bacci G. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 2003; 21 710-715
- 12 Fletcher C DM, Unni K K, Mertens F. (Eds) .WHO Classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon; IARC Press 2002
- 13 Fuchs N, Bielack S S, Epler D, Bieling P, Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998; 9 893-899
- 14 Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol. 1994; 12 1443-1451
- 15 Kaatsch P, Kaletsch U, Spix C, Michaelis J. Jahresbericht 1998: Deutsches Kinderkrebsregister. Mainz, Germany; Johannes-Gutenberg-Universität, Institut für Medizinische Statistik und Information 1999
- 16 Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack S S. Primary metastatic osteosarcoma: Presentation and outcome of 202 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group (COSS) protocols. J Clin Oncol. 2003; 21 2011-2018
- 17 Link M P, Goorin A M, Miser A W, Green A A, Pratt C B, Belasco J B, Pritchard J, Malpas J S, Baker A R, Kirkpatrick J A. et al . The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremities. N Engl J Med. 1986; 314 1600-1606
- 18 Meyers P A, Schwartz C L, Bernstein M. et al . Addition of ifosfamide and muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate improves event-free survival (EFS) in localized osteosarcoma (OS). Proceedings of the American Society of Clinical Oncology. 2001; 20 1463 (abstract)
- 19 Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G, Schwarz R, von Hochstetter A R, Salzer-Kuntschik M, Berdel W E, Jürgens H, Exner G U, Reichardt P, Mayer-Steinacker R, Ewerbeck V, Kotz R, Winkelmann W, Bielack S S. Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2003; 21 334-341
- 20 Ozaki T, Flege S, Liljenqvist U, Hillmann A, Delling G, Salzer-Kuntschik M, Jürgens H, Kotz R, Winkelmann W, Bielack S S. Osteosarcoma of the spine: Experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer. 2002; 94 1069-1077
- 21 Picci P, Sangiorgi L, Rougraff B T, Neff J R, Casadei R, Campanacci M. The relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994; 12 2699-2705
- 22 Picci P, Vanel D, Briccoli A, Talle K, Haakenaasen U, Malaguti C, Monti C, Ferrari C, Bacci G, Saeter G, Alvegard T A. Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol. 2001; 12 1601-1604
- 23 Rosen G, Caparros B, Huvos A G, Kosloff C, Nirenberg A, Cacavio A, Morcove R C, Lane J M, Mehta B, Urban C. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49 1221-1230
- 24 Sanders T G, Parsons III T W. Radiographic imaging of musculoskeletal neoplasia. Cancer Control. 2001; 8 221-231
- 25 Sinha B K, Politi P M. Anthracyclines. Cancer Chemother Biol Response Modif. 1990; 11 45-57
- 26 Smith M A, Ungerleider R S, Horowitz M E, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991; 83 1460-1470
- 27 Sobin L H, Wittekind C. UICC TNM classification of malignant tumors. New York; 6th ed. Wiley 2002
- 28 Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurst C, Berger J, Ritter J, Jurgens H, Gerein V. et al . Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988; 6 329-337
- 29 Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Gobel U. et al . Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol. 1984; 2 617-624
- 30 Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Kotz R, Greenshaw C, Jurgens H, Ritter J, Kusnierz-Glaz C, Erttmann R. et al . Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer. 1990; 66 1703-1710
Dr. med. Silke Flege
Pädiatrische Hämatologie und Onkologie
Klinik und Poliklinik für Kinder- und Jugendmedizin
Universitätsklinikum Münster
Albert-Schweitzer-Straße 33
48129 Münster
eMail: coss@uni-muenster.de